SINGAPORE

Sotrovimab
(sotrovimab for intravenous infusion)

The interim authorization for the sotrovimab emergency therapeutic product by the Health Sciences Authority (HSA) of Singapore is made under Regulations 60A(4) and (5)(b) of the Health Product (Therapeutic Products) Regulations, for use and supply as directed by the Government of Singapore.

Healthcare providers may report adverse events by contacting GSK Singapore at +65 6232 8338 or sending an email to sg.drugsafety@gsk.com.

Our privacy notice explains how we handle the processing of personal data in GSK when someone contacts us in relation to a query, claim or notification of an adverse event.

GlaxoSmithKline Pte Ltd

23 Rochester Park
Singapore 139234

NP-SG-SOT-PINF-220001 May 2022